looking the forward Thank you, you with in We've clinical today. Marianne. significant sharing and progress made details programs, stage to I'm
us. which will the start These our focus III Phase applications. hepatitis key making ECLIPSE be a to We're first excellent program of progress program, our our for this of basis in delta initiating form year. towards continues marketing the Let's half with studies
This III most responses cohorts. with provide We RNA into we the me II suppression multiple HDV in longest move program, XX Phase our XX% of to follow-up program. or some given therapy our detected durable detected presence Before weeks, TND, data, with of viral impressive or refer recap XX% of current the is combination to and below deepening blood. more arm briefly HDV we results. time. potential the stringent of XX, week novo detected SOLSTICE impressively, which out context, XX. therapy encouraging virus patients measure week not our over At our Phase In virologic we patients more target there has not four data, rollover not dive de let achieved target even provides Even confidence patients saw can To at our we methods.
In suggests threshold. for no ECLIPSE which mean This is measurable saw levels. to at with testing target XX% when combination RNA achieve this us forward levels responses across increased cohort the our the five achieved of we the
significant hepatitis for declines because hepatitis and is also B levels antigen levels. observed receiving per At XX% we antigen surface below B combination approximately and reducing surface Importantly, XX both of a in elebsiran virus essential surface IU antigen tobevibart week controlling hepatitis hepatitis XX, participants achieved ml. replication. B finding crucial B is the of This
elebsiran and demonstrated combination of cohorts. the across tobevibart a safety Additionally, all profile favorable
has Fast to which sooner. help status. designation designation FDA. potential significant development our potentially Track garnered The impact from EMA us designations therapy. Drug regulatory and received granted and the breakthrough our of the review this much-needed accelerate designation We've Orphan to speaks support, therapy These has PRIME approach and Our therapy process, could bringing patients
will cure sharing the we B we've looking to I programs. to looking B I'm our hepatitis year. We're functional treatment would a be data. for this functional hepatitis of made and want quarter to in of cure a very milestone we are the excited program; forward data to for with only this our data reiterate our of on functional disease progress forward potentially development that sharing crucial delta, program cure landscape the the we're changing about second this Turning partner. in pursue program. cusp hepatitis the This infectious
with discuss PRO-XTEN progress me discuss oncology the shift let to platform. to Now portfolio significant we've gears the made our
Marianne at event like shared January, I'd deeper results. into compelling in those our data As to dive we've mentioned, investor and
recap the each to for dual hydrophilic, in designed window, a the target dosing This to tissues create platform. into in improved engagement T-cell tumor briefly activated with Before selectively we systemic is microenvironment.
The key PRO-XTEN allowing reduced wider be normal toxicity. get me as acting let engagers The to the higher expressing technology and therapeutic us for program, antigen. allows and shield unstructured potential specifics efficacy masks T-cell are the masked innovative of prevent the a advantage PRO-XTEN
during as nature clot protease gives clotting high We traditional microenvironment.
The universal unmasked the a programs. across ability seen and in to a PRO-XTEN protease cleavable engagers for the access our Importantly, nature enabling hemophilia. and of believe cleavage the demonstrating been clinically approach ALTUVIIIO, PRO-XTEN of the enable sites seen oncology of have could contains potential quickly the with their validated protease-rich also that the three this unmasked. linkers, many regulated us efficient approved allows the in application T-cell an tightly cleaved fluid system limitations its are are overcome ALTUVIIIO masks and tumor cascade, therapy validated confidence platform in efficient in microenvironment activation when to
per tumors, many of rate colorectal signals across the doses note important pretreated cancer. and engager. in these with encouraging HERX-targeted XXX including our of lines exhausted efficacy that we care micrograms Let's patients At therapy, having start were It XX% HERX-targeted cancer had to a and kilogram observed colorectal confirmed response above, multiple treatments. received prior T-cell options with of in VIR-XXXX, standard seen HERX-positive is patients. heavily We've multiple particularly partial all
X-week at of Remarkably, of Additionally, patient A the potential study achieved responses responses. patients bevacizumab cutoff.
Crucially, treatment, patient exhausted for these LONSURF digits. lines the on resistant in highlight through cancer efficacy therapy, we which the agents, as data regimens this hard-to-treat or prior recent a schedule. observed in typically one who put To note on speaks to patients. also for over show current with including in our are single durable last microenvironment every in to compelling a months like who overcome microsatellite a these MSS in rates six plus sustained This progressed to the to case observed these stable presented context, response. HERX-targeted still has like tumors, tumor lines the immunosuppressive was XX it's we've colorectal I'd have cancer which partial of VIR-XXXX's been objective with typically response important results for of HERX-positive suggests colorectal ability immunotherapies. response that multiple investor three event, to dosing our patients
pertuzumab syndrome release encouraging mandatory or favorable including CRS are of schedule pretreated to combination been maintaining The this We're profile. in trastuzumab-based with escalation VIR-XXXX this results, dose an the with which epitope, with an particularly worth high-grade therefore, while optimize setting. earlier enables that has heavily population. profile combination pembrolizumab.
It's strategies, potential continuing in VIR-XXXX We're early line on cytokine without favorable therapies corticosteroids. and every utilizes Our prophylactic exploring binding no strategies noting safety safety efficacy X-week also
VIR-XXXX, dose response this Phase I achieving encouraging impressive to and of Among PSA population Turning response.
This engager nature given our often prostate achieving a patients PSAXX VIR-XXXX Like other corticosteroids in has XX particularly we've early in have the is for seen or T-cell pretreated XX% Notably, use and the PSAXX of cancer, high-grade prophylactic experienced ongoing with dose safety and no in T-cell range, higher masked the T-cell the escalation early the results without profile XXX% efficacious heavily favorable study. X treated engagers. anti-IL-X dose CRS. with or X% PSMA-targeted declines of required stage VIR-XXXX, therapies, Grade been escalation early are results these events achieved minimal with escalation. which including engagers, adverse dose our
any cases we PSMA-targeted dose efficacy hearing room which potentially profile, toxicities of significant been such escalation as believe improve reported and Importantly, off-tumor We're observed have on with our favorable therapies. other safety we further. to on-target there's have continuing not loss, based
meaningful which lines with deeper also see earlier and patients This could with XX prostate to for could we durable for be X significant we benefit a X-week dosing, outcomes frequent efficacy potential which dosing we've various less cancer.
We're responses, in treatment. days. observed half-life exploring by across a higher move potential offer VIR-XXXX's is profile more every which profile, combined The doses, shows to significantly dosing and frequent less to therapy. prostate supported of As actively advantage, of of encouraging safety improve expect patients for cancer especially stages the pharmacokinetic to could
prophylactic for corticosteroids without these Importantly, anti-IL-X been the or have therapies. achieved results need
indications, For and first non-small This study and the seen index of engagers, VR-XXXX, with leveraging and this we're initiate colorectal with PRO-XTEN our has with optimize multiple high-value a learnings successes we're cell our EGFR to we've targeted to We're on our half track dosing from strategy.
Based cancer. on the the address T-cell cancer, VIR-XXXX neck program potential I our year. the to design cancer head engager, in VIR-XXXX. lung the Phase and VIR-XXXX study platform our therapeutic in experience confident to broad other ability T-cell and including achieve
ahead, for we VIR-XXXX dose anticipate sharing ongoing additional Looking from studies our and data VIR-XXXX. escalation
insights progress very these include the our T-cell efficacy for timing In several PRO-XTEN X-week to data platform, dose to landscape programs.
This both The programs ability solid doses further challenging and making to for schedules, expect mature we we believe of present therapies. we're the unmasked for the valuable weekly the oncology dosing still about our into are than is well-positioned every potential dosing from I'm redefine from across data announced, will traditional excited and While at tumors. conclusion, early treatment regimens approaches.
We be the demonstrating the to exact engager optimal will which more validating we're portfolio. provide higher the believe results both both higher
on Our the therapies.
With full our call and unlocking development potential now focused to of Jason. the promising executing these remains that, over team plans I'll hand clinical
